TY - JOUR
T1 - Stereotactic ablative radiotherapy (SABR) for early-stage central lung tumors
T2 - New insights and approaches
AU - Tekatli, H.
AU - Spoelstra, F. O.B.
AU - Palacios, M.
AU - van Sornsen de Koste, J.
AU - Slotman, B. J.
AU - Senan, S.
PY - 2018/9/1
Y1 - 2018/9/1
N2 - The use of stereotactic ablative radiotherapy (SABR) for central lung tumors is increasing. Centrally located lung tumors can be subdivided into two categories, namely the ‘moderately central’ tumors where the planning target volume is located within 2 cm of the proximal bronchial tree, and the ‘ultracentral’ tumors where a planning target volume (PTV) overlaps the trachea or main stem bronchi. The toxicity of SABR appears acceptable when ‘moderately central’ tumors are treated using techniques that comply with organs at risk tolerance doses used for prospective trials and in recent publications. A high toxicity is seen when ultracentral tumors are treated using SABR, and conventional radiotherapy appears more appropriate in such tumors as the true normal organ tolerance doses remain unknown. When ultracentral tumors are treated with non-SABR hypofractionated radiotherapy, a homogenous dose distribution in the planning target volume and limitation of both normal organ maximum point doses and volumes receiving high doses seems to be needed.
AB - The use of stereotactic ablative radiotherapy (SABR) for central lung tumors is increasing. Centrally located lung tumors can be subdivided into two categories, namely the ‘moderately central’ tumors where the planning target volume is located within 2 cm of the proximal bronchial tree, and the ‘ultracentral’ tumors where a planning target volume (PTV) overlaps the trachea or main stem bronchi. The toxicity of SABR appears acceptable when ‘moderately central’ tumors are treated using techniques that comply with organs at risk tolerance doses used for prospective trials and in recent publications. A high toxicity is seen when ultracentral tumors are treated using SABR, and conventional radiotherapy appears more appropriate in such tumors as the true normal organ tolerance doses remain unknown. When ultracentral tumors are treated with non-SABR hypofractionated radiotherapy, a homogenous dose distribution in the planning target volume and limitation of both normal organ maximum point doses and volumes receiving high doses seems to be needed.
UR - http://www.scopus.com/inward/record.url?scp=85050142883&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.lungcan.2018.07.002
DO - https://doi.org/10.1016/j.lungcan.2018.07.002
M3 - Review article
C2 - 30089586
SN - 0169-5002
VL - 123
SP - 142
EP - 148
JO - Lung Cancer
JF - Lung Cancer
ER -